SC209, an EGFR antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002[1][2].
[1]. Alice Yam, et al. Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof. Patent. WO2021247798.
[2]. De Almeida V, et al. Preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian cancer. Gynecologic Oncology, 2018, 149: 50.
















